'Irrelevant' Costs in Healthcare: A Population Study of the Treatment of Schizophrenia in the Province of Manitoba
26 Pages Posted: 17 Jan 2012
Date Written: January 15, 2012
Abstract
Accounting literature provides many examples of how it has helped healthcare decision making. There is no evidence of how healthcare has helped accounting. This is a unique study which views accounting decision making from a non-business perspective of healthcare decision making, through treatment cost interactions. Relationships between illness and non-illness related costs are viewed from a treatment perspective showing that cost interactions are more complex than would be suggested by current accounting decision making models. The result suggests that managerial decision making needs to provide flexibility to allow unique cost interactions which are expected but not quantifiable to be included in healthcare decision metrics. Both financial and non-financial information are shown to be of continued importance in decision making, but we suggest that some healthcare costs may mask themselves as indirect and irrelevant even though they are not.
Keywords: healthcare, costing
JEL Classification: I10, M40
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Accounting for Future Costs in Medical Cost-Effectiveness Analysis
-
Schumpeterian Profits in the American Economy: Theory and Measurement
-
Schumpeterian Profits in the American Economy: Theory and Measurement
-
Estimating the Impact of Medical Innovation: A Case Study of HIV Antiretroviral Treatments
By Mark Duggan and William N. Evans
-
Insurance and Incentives for Medical Innovation
By Alan M. Garber, Charles I. Jones, ...
-
Intellectual Property & External Consumption Effects: Generalizations from Pharmaceutical Markets
-
By Tomas Philipson and Anupam B. Jena
-
Advances in Cost-Effectiveness Analysis of Health Interventions
-
The Welfare Effects of Public Drug Insurance
By Darius N. Lakdawalla and Neeraj Sood
-
Surplus Appropriation from R&D and Health Care Technology Assessment Procedures
By Tomas Philipson and Anupam B. Jena